- Home
- BZAIW vs ICUCW Comparison
BZAIW vs ICUCW Comparison
Compare BZAIW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAIW
- ICUCW
- Stock Information
- Founded
- BZAIW 2010
- ICUCW N/A
- Country
- BZAIW United States
- ICUCW United States
- Employees
- BZAIW 232
- ICUCW 18
- Industry
- BZAIW
- ICUCW Biotechnology: Pharmaceutical Preparations
- Sector
- BZAIW
- ICUCW Health Care
- Exchange
- BZAIW Nasdaq
- ICUCW Nasdaq
- Market Cap
- BZAIW N/A
- ICUCW N/A
- IPO Year
- BZAIW N/A
- ICUCW 2021
- Fundamental
- Price
- BZAIW $1.21
- ICUCW $0.04
- Analyst Decision
- BZAIW
- ICUCW
- Analyst Count
- BZAIW 0
- ICUCW 0
- Target Price
- BZAIW N/A
- ICUCW N/A
- AVG Volume (30 Days)
- BZAIW 233.5K
- ICUCW N/A
- Earning Date
- BZAIW 05-14-2025
- ICUCW N/A
- Dividend Yield
- BZAIW N/A
- ICUCW N/A
- EPS Growth
- BZAIW N/A
- ICUCW N/A
- EPS
- BZAIW N/A
- ICUCW N/A
- Revenue
- BZAIW $1,967,000.00
- ICUCW N/A
- Revenue This Year
- BZAIW N/A
- ICUCW N/A
- Revenue Next Year
- BZAIW N/A
- ICUCW N/A
- P/E Ratio
- BZAIW N/A
- ICUCW N/A
- Revenue Growth
- BZAIW N/A
- ICUCW N/A
- 52 Week Low
- BZAIW $0.42
- ICUCW N/A
- 52 Week High
- BZAIW $0.57
- ICUCW N/A
- Technical
- Relative Strength Index (RSI)
- BZAIW 64.14
- ICUCW 52.26
- Support Level
- BZAIW $1.02
- ICUCW $0.03
- Resistance Level
- BZAIW $1.09
- ICUCW $0.04
- Average True Range (ATR)
- BZAIW 0.22
- ICUCW 0.00
- MACD
- BZAIW 0.03
- ICUCW 0.00
- Stochastic Oscillator
- BZAIW 68.12
- ICUCW 78.38
About BZAIW Blaize Holdings Inc. Warrants
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.